CompletedPhase 2

Non-Ablative Allo HSCT For Hematologic Malignancies or SAA

United States58 participantsStarted 2000-06

Plain-language summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by peripheral stem cell transplantation in treating patients who have hematologic cancer or aplastic anemia.

Who can participate

Age range

70 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Histologically proven high-risk hematologic malignancy * Acute non-lymphocytic leukemia (ANLL) after induction failure, or in first complete remission (CR) with high-risk features, including any of the following: * Stem cell or biphenotypic classification (AML-M0) * Erythroleukemia (AML-M6) * Acute megakaryocytic leukemia (AML-M7) * Cytogenetic markers indicative of poor prognosis * Failure to achieve CR after standard induction therapy * Acute lymphocytic leukemia (ALL) or ANLL in relapse or second or subsequent remission * Chronic myelogenous leukemia (CML) in chronic or accelerated phase * Patients with CML in blast crisis are eligible after reinduction chemotherapy places them in chronic phase * High-risk ALL in first CR with high risk defined by presence of t(4;11), t(9;22) translocation, hyperleukocytosis (initial WBC greater than 30,000/mm\^3), or failure to achieve CR by day 28 after standard induction * No T-cell ALL or t(8;14) positive B-cell ALL in first remission with hyperleukocytosis * Myelodysplastic syndrome by peripheral blood smear and bone marrow examination * Refractory to medical management OR * Cytogenetic abnormalities predictive of transformation into acute leukemia including 5q-, 7q-, monosomy 7, and trisomy 8 OR * Evidence of evolution to AML (e.g., refractory anemia with excess blasts (RAEB) or RAEB in transformation) * Multiple myeloma, non-Hodgkin's lymphoma (NHL)…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Evaluation of Donor Engraftment

Timeframe: at 28 days

Trial details

NCT IDNCT00006379

SponsorCase Comprehensive Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2004-01

View on ClinicalTrials.gov More Chronic Myeloproliferative Disorders trials